Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
Microbot Medical (NASDAQ: MBOT) announced on Nov 5, 2025 that its LIBERTY® Endovascular Robotic System is now commercially available in the U.S. via a Limited Market Release focused on selected high‑procedure‑volume regions. The system is described as the first FDA‑cleared single‑use, remotely operated robotic system for peripheral endovascular procedures; the company received FDA 510(k) clearance in September. The LMR will collect real‑world feedback to guide responsible growth, supported by a newly hired core commercial team and a third‑party logistics partner. A Full Market Release is expected at the Society of Interventional Radiology meeting in April 2026.
Microbot Medical (NASDAQ: MBOT) ha annunciato il 5 novembre 2025 che il suo LIBERTY® Endovascular Robotic System è ora disponibile commercialmente negli Stati Uniti tramite un Rilascio di Mercato Limitato focalizzato su regioni ad alto volume di procedure. Il sistema è descritto come il primo sistema robotico per endovascolare periferica a uso singolo e controllato a distanza approvato dalla FDA; l'azienda ha ricevuto l’approvazione FDA 510(k) a settembre. L'MMR raccoglierà feedback reali per guidare una crescita responsabile, supportata da un nuovo team commerciale principale assunto e da un partner logistico terzo. Un Rilascio sul Mercato Completo è previsto durante l'incontro della Society of Interventional Radiology nell'aprile 2026.
Microbot Medical (NASDAQ: MBOT) anunció el 5 de noviembre de 2025 que su LIBERTY® Endovascular Robotic System ya está disponible comercialmente en los EE. UU. a través de una Restricción de Mercado Limitado centrada en regiones seleccionadas de alto volumen de procedimientos. El sistema se describe como el primer sistema robótico para procedimientos endovasculares periféricos de uso único y operado a distancia aprobado por la FDA; la empresa recibió la aprobación FDA 510(k) en septiembre. El LMR recogerá retroalimentación del mundo real para guiar un crecimiento responsable, respaldado por un nuevo equipo comercial central contratado y un socio logístico tercero. Se espera un Liberación Total del Mercado en la reunión de la Society of Interventional Radiology en abril de 2026.
마이크로봇 메디컬(Microbot Medical) (나스닥: MBOT)은 2025년 11월 5일에 LIBERTY® Endovascular Robotic System이 미국에서 제한적 시장 출시를 통해 상용화되었으며, 고처리량 지역을 중심으로 선정되었습니다. 이 시스템은 단일 사용, 원격 조작이 가능한 최초의 FDA 인증 말단혈관 절차용 로봇 시스템으로 설명되며; 회사는 9월 FDA 510(k) 승인을 받았다고 합니다. LMR은 실제 세계 피드백을 수집해 책임 있는 성장을 이끌 것이며, 신규 채용된 핵심 커머셜 팀과 제3자 물류 파트너가 지원합니다. 전면적 시장 출시는 2026년 4월의 Interventional Radiology 학회에서 예상됩니다.
Microbot Medical (NASDAQ : MBOT) a annoncé le 5 novembre 2025 que son LIBERTY® Endovascular Robotic System est désormais commercialisé aux États-Unis via une Sortie de Marché Restreinte axée sur des régions à haut volume de procédures. Le système est décrit comme le premier système robotisé endovasculaire périphérique à utilisation unique et piloté à distance ayant obtenu l'approbation FDA ; la société a reçu l’autorisation FDA 510(k) en septembre. Le LMR recueillera des retours du monde réel pour guider une croissance responsable, soutenue par une nouvelle équipe commerciale principale embauchée et un partenaire logistique tiers. Une Sortie sur Marché Complet est attendue lors de la réunion de la Society of Interventional Radiology en avril 2026.
Microbot Medical (NASDAQ: MBOT) kündigte am 5. November 2025 an, dass sein LIBERTY® Endovascular Robotic System nun in den USA über eine Begrenzte Markteinführung in ausgewählten Regionen mit hohem Prozedurvolumen kommerziell erhältlich ist. Das System wird als erstes FDA-geprüftes Einweg-, ferngesteuertes Roboter-System für periphere Endovaskuläre Verfahren beschrieben; das Unternehmen erhielt die FDA 510(k) Freigabe im September. Die LMR wird Real-World-Feedback sammeln, um verantwortliches Wachstum zu steuern, unterstützt von einem neu eingestellten Kern-Verkaufsteam und einem Drittanbieter-Logistikpartner. Eine Vollständige Markteinführung wird voraussichtlich auf dem Meeting der Society of Interventional Radiology im April 2026 erfolgen.
Microbot Medical (NASDAQ: MBOT) أعلنت 5 نوفمبر 2025 أن نظام LIBERTY® Endovascular Robotic System أصبح متاحًا تجارياً في الولايات المتحدة عبر إصدار محدود للسوق يركّز على مناطق ذات حجم إجراء عالٍ محدد. يوصف النظام بأنه أول نظام روبوتي للإجراءات الوعائية الطرفية ذو استخدام واحد ويُدار عن بُعد مع اعتماد FDA؛ تلقت الشركة إعتماد FDA 510(k) في سبتمبر. سيجمع LMR ملاحظات من الواقع الواقعي لتوجيه نمو مسؤول، مدعوماً من فريق مبيعات أساسي جديد تعيينه وشريك لوجستي من طرف ثالث. من المتوقع إطلاق السوق الكامل في اجتماع الجمعية التصوير التداخلي الإشعاعي في أبريل 2026.
- Received FDA 510(k) clearance in September 2025
- LIBERTY commercially available in U.S. as of Nov 5, 2025
- Secured a third‑party logistics partner to support distribution
- Expanded core commercial leadership team ahead of launch
- Targeting Full Market Release at SIR in April 2026
- Current rollout is a Limited Market Release confined to selected high‑volume regions
- Full commercial launch postponed until April 2026 (SIR meeting)
Insights
LIBERTY® begins U.S. limited commercial release, following FDA 510(k) clearance and commercial readiness steps.
The company is introducing the LIBERTY® Endovascular Robotic System into a Limited Market Release in selected high‑volume U.S. regions after receiving FDA 510(k) clearance in September. The rollout includes a hired core commercial team and a third‑party logistics partner to support early users and collect real‑world feedback to refine deployment and training.
Key dependencies include successful adoption by early users and the quality of the real‑world data the company collects; the announcement explicitly frames the LMR as a way to guide responsible growth and prepare for a Full Market Release at the Society of Interventional Radiology meeting in
Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial Team and Establishing Logistic Partnership
Interest and Overwhelmingly Positive Feedback from Physicians and Hospital Administrators at Recent Meetings Validates Limited Market Release of LIBERTY®
HINGHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that its LIBERTY® System, the first FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures, is now commercially available in the U.S. The Limited Market Release (LMR) will introduce LIBERTY® to selected high procedure volume regions where the Company already experienced preliminary demand for LIBERTY®. The LMR will focus on collecting real-world insights from potential high-volume users to guide responsible growth and ensure consistent quality and performance, leading to the expected Full Market Release (FMR) during the Society of Interventional Radiology (SIR), the largest U.S. medical conference for Interventional Radiology, in April 2026.
“We are excited to enter the commercialization phase of LIBERTY®. We are building a new robotic category with the introduction of LIBERTY®, the world’s first single-use robotic system. Launching just weeks after announcing FDA clearance, we believe that we have demonstrated the strength of our team and the unique innovation behind LIBERTY®,” commented Harel Gadot, CEO, President and Chairman. “Building on the strong interest and feedback we have received so far from physicians and hospital administrators, the limited market release is expected to enable us to responsibly support early adopters and lay the groundwork for a full market launch at the Society of Interventional Radiology meeting in April.”
Since receiving the FDA 510(k) clearance for the LIBERTY® System in September, the Company has advanced its commercial readiness by securing a third-party logistics partner and expanding its commercial leadership team to ensure a fully supported and successful limited market release.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Commercialization Robotics MedTech MBOT News Endovascular Robotics Medical Robotics Innovation
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f9906051-4491-4f55-9a79-2d0e2b0d1413
FAQ
What did Microbot Medical (MBOT) announce on November 5, 2025 about LIBERTY?
When did LIBERTY receive FDA clearance and what type was it for MBOT?
What regions will MBOT target during the LIBERTY Limited Market Release?
How is Microbot supporting LIBERTY’s limited U.S. launch (MBOT)?
When does Microbot plan the Full Market Release of LIBERTY (MBOT)?
What is the purpose of LIBERTY’s Limited Market Release for MBOT shareholders?
